ADV1212: A Phase I Study of Crizotinib (IND#105573) In Combination with Conventional Chemotherapy For Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma


Solid Tumor : Relapsed or refractory solid tumors or anaplastic large cell lymphoma


This is a phase I study of a drug called crizotinib in combination with chemotherapy.

Crizotinib is considered experimental because we are not sure if it will work on this disease in humans. This is called a Phase I study because the goal is to find the highest dose of crizotinib in combination with chemotherapy that we can give safely. The study is split into two parts, Part A and Part B. In Part A, crizotinib will be given in combination with topotecan and cyclophosphamide. In Part B, crizotinib will be given in combination with vincristine, doxorubicin and dexrazoxane.

Treatment assignment will depend on the type of cancer and the chemotherapy treatments received in the past.


Eligibility criteria, among others include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.